Onset of action of fexofenadine hydrochloride 60 mg/ pseudoephedrine hydrochloride 120 mg in subjects aged ≥ 12 years with moderate to severe seasonal allergic Rhinitis: A pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1658-1669

  Berkowitz, Robert B ^a   McCafferty, Frank ^a   Lutz, Cheryl ^a   Bazelmans, Donna ^a   Godfrey, Penny ^a   Meeves, Suzanne ^b   Liao, Yuning ^b   Georges, George ^b  

^a Rx Research   (United States)

^b SANOFI   (France)

Author keywords

allergen exposure unit; fexofenadine; onset of action, pooled analysis; pseudoephedrine; seasonal allergic rhinitis

Indexed keywords

ALLEGRA D; ALLERGEN; FEXOFENADINE; PLACEBO; PSEUDOEPHEDRINE;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; COUGHING; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; EAR PRURITUS; EYE ALLERGY; HAY FEVER; HUMAN; NASAL PRURITUS; NAUSEA; NOSE MUCUS; OCULAR PRURITUS; PARALLEL DESIGN; PHARYNGITIS; REGRESSION ANALYSIS; RHINORRHEA; SCORING SYSTEM; SINGLE DRUG DOSE; SNEEZING; SNIFFING; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; THROAT IRRITATION;

ADULT; ALLERGENS; ANTI-ALLERGIC AGENTS; DEMOGRAPHY; DOUBLE-BLIND METHOD; EPHEDRINE; FEMALE; HUMANS; MALE; PLACEBOS; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; TREATMENT OUTCOME;

EID: 33751568291     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.023     Document Type: Article

References (23)

1. Bousquet J., van Cauwenberge P., and Khaltaev N.Aria Workshop Group and the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 Suppl 5 (2001) S147-S334
2. Settipane R.A. Rhinitis: A dose of epidemiological reality. Allergy Asthma Proc 24 (2003) 147-154
3. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 3517 (1998) 1225-1232
4. van Cauwenberge P., Bachert C., Passalacqua G., et al., European Academy of Allergology and Clinical Immunology. Consensus statement on the treatment of allergic rhinitis. Allergy 55 (2000) 116-134
5. van Cauwenberge P., and Juniper E.F. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Fxp Allergy 30 (2000) 891-899
6. Howarth P., Stern M.A., Roi L., et al. Double-blind, placebocontrolled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 104 (1999) 927-933
7. Wilson A.M., Orr L.C., Coutie W.J., et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Fxp Allergy 32 (2002) 126-132
8. Berger W.E., Schenkel E.J., Mansfield L.E., and Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allerg Asthma Immunol 89 (2002) 485-491
9. Horak F., Toth J., Marks B., et al. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 53 (1998) 849-856
10. Sussman G.L., Mason J., Compton D., et al. The efficacy and safety of fexofenadine HCI and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 104 (1999) 100-106
11. Schenkel E., Corren J., and Murray J.J. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc 23 (2002) 325-330
12. Kaiser H.B., Banov C.H., Berkowitz R.R., et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. Am J Ther 5 (1998) 245-251
13. Berkowitz R.B., Woodworth G.G., Lutz C., et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/ pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma lmmunol 89 (2002) 38-45
14. Berkowitz R.B., McCafferty F., Lutz C., et al. Fexofenadine HCI 60 mg/pseudoephedrine HCI 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhini tis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc 25 (2004) 335-343
15. Horak F., Jager S., Toth J., and Berger U. Efficacy and tolerability of astemizole-D and loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. Arzneimittelforschung 46 (1996) 1077-1081
16. Georgitis J.W., Meltzer F.O., Kaliner M., et al. Onset-ofaction for antihistamine and decongestant combinations during an outdoor challenge. Ann Allergy Asthma Immunol 84 (2000) 451-459
17. Available at:. US Food and Drug Administration, Center for Drug Evaluation and Research, and Guidance for Industry. Allergic rhinitis: Clinical development programs for drug products. Accessed July 8. Draft guidance (2005). http://www.fda.gov/cder/guidance/2718dft.htm#P371_60869
18. Day J.H., Briscoe M.P., Welsh A., et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma lmmunol 79 (1997) 533-540
19. Abstract. Berkowitz R.B., Woodworth G.G., Lutz C., et al. Singlecenter, double-blind, randomized, parallel study comparing onset of action, efficacy, and safety of a single dose of fexofenadine HCI (Allegra) 180 mg compared with placebo in treating seasonal allergic rhinitis patients in an allergen exposure unit. Allergy Asthma Proc. 24 (2003) 211
20. Day J.H., Briscoe M.P., Rafeiro E., et al. Randomized doubleblind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: Duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 25 (2004) 59-68
21. Horak F., Zieglmayer U.P., Zieglmayer R., et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: A pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 22 (2006) 151-157
22. Stubner P., Zieglmayer R., and Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: Randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit-the Vienna Challenge Chamber (VCC). Curr Med Res Opin 20 (2004) 891-902
23. Day J.H., Briscoe M.P., Rafeiro F., and Ratz J.D. Comparative clinical efficacy, onset and duration of action of levo cetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the environmental exposure unit (FFU). Int J Clin Pract 58 (2004) 109-118